Research

Published research I’ve contributed to, written up properly — the full data, the methods, the numbers that didn’t work, and a plain-language route in for readers who aren’t specialists.

Everything here starts from one paper: Design and evaluation of triple-doped nano-hydroxyapatite (Mg/Si/Zn-HAp) as multi-step intelligent scaffold for bone healing, published in Hybrid Advances 13 (2026), doi:10.1016/j.hybadv.2026.100657. It was built by 26 researchers across 11 faculties and 2 universities in Syria — medicine, pharmacy, chemistry, biotechnology, environmental, mechanical and mechatronics engineering, nursing and agriculture. The material is a hydroxyapatite that senses the acidity of an inflamed wound and releases more of its antibacterial zinc in response.

I’m a mechatronics engineer, not a chemist. My colleagues in pharmacy and chemistry did the synthesis and the assays; my interest is in what the material looks like when you read it as a control system, and in how you actually manufacture one. That’s the angle these write-ups take.

Where to start. If you want the human story of how the team was built, read the announcement. If you want to understand how the material works, read the closed-loop breakdown. If you want methods and numbers, go straight to the technical data sheet. Arabic versions of all four pages are listed below.

Preprints — quantitative-trading research (2026)

#

Two companion papers from my trading-strategy research programme at BeInMedia (Nmo AI), both distributed on SSRN in September 2026:

• Opening-Range Breakout Does Not Survive Trading Costs: A Pre-Registered 225-Cell Study on Sixteen Years of Futures Data — SSRN, doi:10.2139/ssrn.7428398.
• A Machine-Verified Claims Ledger for Trading-Strategy Research — SSRN, doi:10.2139/ssrn.7428478.

The first is the flagship study: the most-taught intraday strategy, tested the way we wished every strategy were tested — pre-registered, costs first, controls frozen in advance. The second describes the verification machinery behind it, where every published number is a claim that must re-derive from committed evidence. The whole programme is covered end to end, in plain language with the code open, in the Trading Strategy Finder project series.